These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

672 related articles for article (PubMed ID: 24631838)

  • 1. A diverse array of cancer-associated MTOR mutations are hyperactivating and can predict rapamycin sensitivity.
    Grabiner BC; Nardi V; Birsoy K; Possemato R; Shen K; Sinha S; Jordan A; Beck AH; Sabatini DM
    Cancer Discov; 2014 May; 4(5):554-63. PubMed ID: 24631838
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vascular tumors have increased p70 S6-kinase activation and are inhibited by topical rapamycin.
    Du W; Gerald D; Perruzzi CA; Rodriguez-Waitkus P; Enayati L; Krishnan B; Edmonds J; Hochman ML; Lev DC; Phung TL
    Lab Invest; 2013 Oct; 93(10):1115-27. PubMed ID: 23938603
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Point mutations of the mTOR-RHEB pathway in renal cell carcinoma.
    Ghosh AP; Marshall CB; Coric T; Shim EH; Kirkman R; Ballestas ME; Ikura M; Bjornsti MA; Sudarshan S
    Oncotarget; 2015 Jul; 6(20):17895-910. PubMed ID: 26255626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Enigma of Rapamycin Dosage.
    Mukhopadhyay S; Frias MA; Chatterjee A; Yellen P; Foster DA
    Mol Cancer Ther; 2016 Mar; 15(3):347-53. PubMed ID: 26916116
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors.
    Hassan B; Akcakanat A; Sangai T; Evans KW; Adkins F; Eterovic AK; Zhao H; Chen K; Chen H; Do KA; Xie SM; Holder AM; Naing A; Mills GB; Meric-Bernstam F
    Oncotarget; 2014 Sep; 5(18):8544-57. PubMed ID: 25261369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CC-223, a Potent and Selective Inhibitor of mTOR Kinase: In Vitro and In Vivo Characterization.
    Mortensen DS; Fultz KE; Xu S; Xu W; Packard G; Khambatta G; Gamez JC; Leisten J; Zhao J; Apuy J; Ghoreishi K; Hickman M; Narla RK; Bissonette R; Richardson S; Peng SX; Perrin-Ninkovic S; Tran T; Shi T; Yang WQ; Tong Z; Cathers BE; Moghaddam MF; Canan SS; Worland P; Sankar S; Raymon HK
    Mol Cancer Ther; 2015 Jun; 14(6):1295-305. PubMed ID: 25855786
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Switch in signaling control of mTORC1 activity after oncoprotein expression in thyroid cancer cell lines.
    Malaguarnera R; Chen KY; Kim TY; Dominguez JM; Voza F; Ouyang B; Vundavalli SK; Knauf JA; Fagin JA
    J Clin Endocrinol Metab; 2014 Oct; 99(10):E1976-87. PubMed ID: 25029414
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protein phosphatase 2A and DNA-dependent protein kinase are involved in mediating rapamycin-induced Akt phosphorylation.
    Li Y; Wang X; Yue P; Tao H; Ramalingam SS; Owonikoko TK; Deng X; Wang Y; Fu H; Khuri FR; Sun SY
    J Biol Chem; 2013 May; 288(19):13215-24. PubMed ID: 23536185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanistically distinct cancer-associated mTOR activation clusters predict sensitivity to rapamycin.
    Xu J; Pham CG; Albanese SK; Dong Y; Oyama T; Lee CH; Rodrik-Outmezguine V; Yao Z; Han S; Chen D; Parton DL; Chodera JD; Rosen N; Cheng EH; Hsieh JJ
    J Clin Invest; 2016 Sep; 126(9):3526-40. PubMed ID: 27482884
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renal tumours in a Tsc2(+/-) mouse model do not show feedback inhibition of Akt and are effectively prevented by rapamycin.
    Yang J; Kalogerou M; Samsel PA; Zhang Y; Griffiths DF; Gallacher J; Sampson JR; Shen MH
    Oncogene; 2015 Feb; 34(7):922-31. PubMed ID: 24632604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual mTORC1/2 inhibition in a preclinical xenograft tumor model of endometrial cancer.
    Korets SB; Musa F; Curtin J; Blank SV; Schneider RJ
    Gynecol Oncol; 2014 Feb; 132(2):468-73. PubMed ID: 24316308
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic and pharmacologic evidence that mTOR targeting outweighs mTORC1 inhibition as an antimyeloma strategy.
    Chen X; Díaz-Rodríguez E; Ocio EM; Paiva B; Mortensen DS; Lopez-Girona A; Chopra R; Miguel JS; Pandiella A
    Mol Cancer Ther; 2014 Feb; 13(2):504-16. PubMed ID: 24431075
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical characterization of OSI-027, a potent and selective inhibitor of mTORC1 and mTORC2: distinct from rapamycin.
    Bhagwat SV; Gokhale PC; Crew AP; Cooke A; Yao Y; Mantis C; Kahler J; Workman J; Bittner M; Dudkin L; Epstein DM; Gibson NW; Wild R; Arnold LD; Houghton PJ; Pachter JA
    Mol Cancer Ther; 2011 Aug; 10(8):1394-406. PubMed ID: 21673091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GSK3 is required for rapalogs to induce degradation of some oncogenic proteins and to suppress cancer cell growth.
    Koo J; Wang X; Owonikoko TK; Ramalingam SS; Khuri FR; Sun SY
    Oncotarget; 2015 Apr; 6(11):8974-87. PubMed ID: 25797247
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Compensatory Increase of Transglutaminase 2 Is Responsible for Resistance to mTOR Inhibitor Treatment.
    Cao J; Huang W
    PLoS One; 2016; 11(2):e0149388. PubMed ID: 26872016
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distinct signaling mechanisms of mTORC1 and mTORC2 in glioblastoma multiforme: a tale of two complexes.
    Jhanwar-Uniyal M; Gillick JL; Neil J; Tobias M; Thwing ZE; Murali R
    Adv Biol Regul; 2015 Jan; 57():64-74. PubMed ID: 25442674
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient-derived xenografts of triple-negative breast cancer reproduce molecular features of patient tumors and respond to mTOR inhibition.
    Zhang H; Cohen AL; Krishnakumar S; Wapnir IL; Veeriah S; Deng G; Coram MA; Piskun CM; Longacre TA; Herrler M; Frimannsson DO; Telli ML; Dirbas FM; Matin AC; Dairkee SH; Larijani B; Glinsky GV; Bild AH; Jeffrey SS
    Breast Cancer Res; 2014 Apr; 16(2):R36. PubMed ID: 24708766
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumor activities of ATP-competitive inhibitors of mTOR in colon cancer cells.
    Blaser B; Waselle L; Dormond-Meuwly A; Dufour M; Roulin D; Demartines N; Dormond O
    BMC Cancer; 2012 Mar; 12():86. PubMed ID: 22401294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MLN0128, an ATP-competitive mTOR kinase inhibitor with potent in vitro and in vivo antitumor activity, as potential therapy for bone and soft-tissue sarcoma.
    Slotkin EK; Patwardhan PP; Vasudeva SD; de Stanchina E; Tap WD; Schwartz GK
    Mol Cancer Ther; 2015 Feb; 14(2):395-406. PubMed ID: 25519700
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The mTOR kinase inhibitors, CC214-1 and CC214-2, preferentially block the growth of EGFRvIII-activated glioblastomas.
    Gini B; Zanca C; Guo D; Matsutani T; Masui K; Ikegami S; Yang H; Nathanson D; Villa GR; Shackelford D; Zhu S; Tanaka K; Babic I; Akhavan D; Lin K; Assuncao A; Gu Y; Bonetti B; Mortensen DS; Xu S; Raymon HK; Cavenee WK; Furnari FB; James CD; Kroemer G; Heath JR; Hege K; Chopra R; Cloughesy TF; Mischel PS
    Clin Cancer Res; 2013 Oct; 19(20):5722-32. PubMed ID: 24030701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.